

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

VOLUNTARY ANNOUNCEMENT

REVASCULARIZATION DEVICE TIGERTRIEVER® OF RAPID MEDICAL, AN ASSOCIATE COMPANY OF MICROPORT NEUROTECH, WAS APPROVED FOR COMMERCIALIZATION

This announcement is made by MicroPort NeuroTech Limited (the “**Company**” or “**MicroPort NeuroTech**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed on the latest business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that Tigertriever® Revascularization Device (“**Tigertriever® Revascularization Device**”), a flagship product of Rapid Medical Ltd. (“**Rapid Medical**”), an associate company of MicroPort NeuroTech has recently been approved for commercialization by the National Medical Products Administration (國家藥品監督管理局) (“**NMPA**”). Tigertriever® Revascularization Device has been admitted to the NMPA’s innovative medical device special review and approval procedure (the “**Green Path**”) in May 2020.

Tigertriever® Revascularization Device is the world’s first adjustable stent retriever with full visualization. Its controllable expansion technology is the first of its kind in the world, which can better adapt to the size of occluded blood vessels in patients with acute ischemic stroke, while having high embolization ability and low vascular injury rate. During the operation, the physicians can safely deliver the product to the lesion by controlling the degree of expansion of the product and the radial force applied to the blood vessel and thrombus in real time, making the release process more accurate and improving the success

rate of thrombus removal; when withdrawing, the physicians can also moderately shrink the product to reduce the radial force, thereby reducing the disturbance and damage to the sensitive and fragile vessel wall. Tigertriever® Revascularization Device obtained CE Marking in the European Union in May 2018 and obtained approval from the United States Food and Drug Administration (“FDA”) in March 2021, and has been applied clinically in many countries and areas such as Europe, the United States, Canada and South America. In respect of the treatment of acute ischemic stroke, Tigertriever® Revascularization Device is expected to improve the postoperative vascular recanalization rate and improve the quality of life of patients with acute ischemic stroke.

Rapid Medical is a company headquartered in Israel that specializes in the research, development, production and sales of innovative medical devices for neurovascular endotherapy. The Company has made several rounds of investment in Rapid Medical and is currently its largest shareholder. The Company is the exclusive distributor in Greater China for the Tigertriever® Revascularization Device, the Tigertriever® 13 Revascularization Device and all iterations of the Tigertriever®.

By order of the Board
MicroPort NeuroTech Limited
Mr. Peng Bo
Chairman

Hong Kong, 18 August, 2023

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Mr. Peng Bo, Mr. Wang Lin and Ms. Wu Xia as the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung as the independent non-executive directors.